STOCK TITAN

Akebia (NASDAQ: AKBA) director Myles Wolf granted RSUs and options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Akebia Therapeutics director Myles Wolf received equity awards as part of non-employee director compensation. He was granted 35,700 shares of Common Stock in the form of restricted stock units and a stock option for 53,600 shares at an exercise price of $1.02 per share. Both the RSUs and the option vest 100% on the first anniversary of the June 17, 2026 grant date, or earlier immediately before the first annual stockholder meeting after the grant, if that occurs sooner, subject to his continued service. Following the award, he directly owns 169,081 Common Shares and holds the newly granted option for 53,600 underlying shares.

Positive

  • None.

Negative

  • None.
Insider Wolf Myles
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to buy) 53,600 $0.00 --
Grant/Award Common Stock 35,700 $0.00 --
Holdings After Transaction: Stock Option (Right to buy) — 53,600 shares (Direct, null); Common Stock — 169,081 shares (Direct, null)
Footnotes (1)
  1. The restricted stock units (the "RSUs") were granted by the Issuer pursuant to its 2023 Stock Incentive Plan (the "2023 Plan"), as provided by the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Program (the "Program"). The RSUs will vest in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continuous service to the Issuer through such vesting date. The option to purchase shares of the Issuer's common stock (the "Stock Option") was granted by the Issuer pursuant to the 2023 Plan, as provided by the Program. The Stock Option will vest and become exercisable in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continuous service to the Issuer through such vesting date.
RSU grant 35,700 shares Restricted stock units granted June 17, 2026
Stock option grant 53,600 shares Option covering common stock granted June 17, 2026
Option exercise price $1.02 per share Conversion or exercise price of new option
Shares after transaction 169,081 shares Common stock directly owned following grant
Option expiration June 17, 2036 Expiration date of stock option
RSU vesting 100% after 1 year Full vesting on first anniversary or earlier before annual meeting
restricted stock units financial
"The restricted stock units (the "RSUs") were granted by the Issuer"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
2023 Stock Incentive Plan financial
"were granted by the Issuer pursuant to its 2023 Stock Incentive Plan"
Non-Employee Director Compensation Program financial
"as provided by the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Program"
Stock Option financial
"The option to purchase shares of the Issuer's common stock (the "Stock Option")"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
vest in full (100%) financial
"The RSUs will vest in full (100%) on the first anniversary"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Wolf Myles

(Last)(First)(Middle)
C/O AKEBIA THERAPEUTICS, INC.
245 FIRST ST.

(Street)
CAMBRIDGE MASSACHUSETTS 02142

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Akebia Therapeutics, Inc. [ AKBA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/17/2026A35,700(1)A$0.00169,081D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to buy)$1.0206/17/2026A53,60006/17/2027(2)06/17/2036Common Stock53,600$0.0053,600D
Explanation of Responses:
1. The restricted stock units (the "RSUs") were granted by the Issuer pursuant to its 2023 Stock Incentive Plan (the "2023 Plan"), as provided by the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Program (the "Program"). The RSUs will vest in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continuous service to the Issuer through such vesting date.
2. The option to purchase shares of the Issuer's common stock (the "Stock Option") was granted by the Issuer pursuant to the 2023 Plan, as provided by the Program. The Stock Option will vest and become exercisable in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continuous service to the Issuer through such vesting date.
Remarks:
/s / Carolyn Rucci, attorney-in-fact for Myles Wolf06/22/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What equity awards did Akebia Therapeutics (AKBA) director Myles Wolf receive?

Myles Wolf received 35,700 restricted stock units and a stock option for 53,600 Akebia Therapeutics common shares. Both grants are compensation awards under the company’s 2023 Stock Incentive Plan and its non-employee director compensation program.

What is the exercise price and term of Myles Wolf’s new Akebia (AKBA) stock option?

The stock option granted to Myles Wolf covers 53,600 shares at an exercise price of $1.02 per share. It was granted June 17, 2026 and is scheduled to expire on June 17, 2036 if not exercised, subject to plan terms.

When do Myles Wolf’s Akebia Therapeutics (AKBA) RSUs and options vest?

Both the 35,700 restricted stock units and the 53,600-share stock option vest 100% on the first anniversary of the June 17, 2026 grant date, or earlier immediately before the first annual stockholder meeting after grant, contingent on his continuous service.

How many Akebia Therapeutics (AKBA) shares does Myles Wolf own after these grants?

After the June 17, 2026 equity awards, Myles Wolf directly holds 169,081 shares of Akebia Therapeutics common stock. He also holds a stock option covering 53,600 additional common shares that will become exercisable after vesting conditions are met.

Under which plans were Myles Wolf’s Akebia (AKBA) equity awards granted?

The restricted stock units and stock option were granted under Akebia’s 2023 Stock Incentive Plan. They were provided pursuant to the company’s Fifth Amended and Restated Non-Employee Director Compensation Program governing director equity compensation.